Risperdal Lawsuits Move Forward, With Rescheduling of Gynecomastia Trials in Pennsylvania Litigation, Bernstein Liebhard LLP Reports
New York, New York (PRWEB) September 26, 2014 -- Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) that allege the use of the antipsychotic medication caused men and boys to develop gynecomastia (male breast growth) continue to move forward in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to an Order dated September 24, 2014, the Court has rescheduled the proceeding’s next three trials, the first of which had been set to begin on September 29, 2014. That case will now go to trial on November 3, 2014. (Goldenberg vs. Janssen Pharmaceuticals, Inc. Etal, Case No. 130201719) The start of the second trial has been moved from November 3, 2014 to January 3, 2015. (PP Etal vs. Ortho-McNeil-Janssen-Pharmaceuticals, Inc., Case No. 1204-01997) The third trial is now scheduled to begin in February on a date yet to be determined by the Court. (WC Etal Vs Janssen Pharmaceuticals, Inc. Etal, 1303-01803).
“Our Firm is representing a number of clients who have filed Risperdal gynecomastia claims in this litigation. We look forward to the commencement of these three trials,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.
Risperdal Litigation
According to court documents, more than 700 Risperdal lawsuits are currently pending in the Pennsylvania litigation. All of these complaints, many of which were filed on behalf of children, allege that the medication caused serious side effects, including gynecomastia in boys. The lawsuits also accuse Johnson & Johnson and Janssen Pharmaceuticals of concealing these risks, and of improperly marketing the drug for unapproved uses. (In Re: Risperdal Litigation, Case Number 100300296).
In November 2013, Johnson & Johnson and Janssen Pharmaceuticals agreed to pay $2.2 million to settle charges brought by the U.S. Department of Justice involving the marketing of Risperdal and other medications. While the companies did not admit any wrongdoing in resolving civil charges regarding the promotion of Risperdal for off-label use in children, they did plead guilty to a criminal misdemeanor and acknowledged that they had improperly marketed the drug for use in elderly dementia patients. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Alleged victims of Risperdal and gynecomastia may be entitled to compensation for medical bills, lost wages, emotional distress, and other damages related to their condition. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Risperdal Lawsuit Information Center, http://www.risperdallawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article